Skip to main content

Pegfilgrastim








Pegfilgrastim


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search


Pegfilgrastim
Clinical dataTrade names

originally Neulasta, other brand names worldwide[1]

AHFS/Drugs.com


Monograph

MedlinePlus

a607058

License data



  • EU EMA: by INN


Pregnancy
category



  • US: C (Risk not ruled out)


ATC code


  • L03AA13 (WHO)


Legal statusLegal status



  • US: ℞-only



Pharmacokinetic dataElimination half-life


15–80 hrs
Identifiers

CAS Number


  • 208265-92-3 ☑Y


IUPHAR/BPS

  • 6969


DrugBank


  • DB00019 ☑Y


ChemSpider

  • none


UNII

  • 3A58010674


KEGG


  • D06889 ☑Y


ChEMBL


  • CHEMBL1201568 ☒N


ECHA InfoCard

100.169.155 Edit this at Wikidata
Chemical and physical dataFormula

C845H1343N223O243S9 + PEG
Molar mass

39,000 g/mol

 ☒N☑Y (what is this?)  (verify)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[2]


Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]


Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[4][3]


In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.[5]


As of 9-22-15 a 6 MG/0.6ML dose costs $15,016.29 in the United States.



Biosimilars[edit]


In July 2016 the US FDA rejected a biosimilar application from Sandoz.[6]


In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.[6]



References[edit]




  1. ^ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016


  2. ^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.


  3. ^ ab Drugs.com: Pegfilgrastim


  4. ^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.


  5. ^ Langreth, Robert (June 29, 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em


  6. ^ ab US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016




External links[edit]


  • Neulasta

  • Neulasta full prescribing information

  • Neulasta Onpro kit Healthcare Provider Instructions for Use












Retrieved from "https://en.wikipedia.org/w/index.php?title=Pegfilgrastim&oldid=843666878"





Navigation menu

























(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.668","walltime":"0.806","ppvisitednodes":"value":5055,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":223120,"limit":2097152,"templateargumentsize":"value":4373,"limit":2097152,"expansiondepth":"value":16,"limit":40,"expensivefunctioncount":"value":1,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":5048,"limit":5000000,"entityaccesscount":"value":1,"limit":400,"timingprofile":["100.00% 547.043 1 -total"," 69.78% 381.712 1 Template:Drugbox"," 49.12% 268.704 1 Template:Infobox"," 14.63% 80.024 14 Template:Navbox"," 13.98% 76.453 1 Template:Reflist"," 12.47% 68.223 16 Template:Unbulleted_list"," 11.43% 62.545 1 Template:Cite_news"," 5.90% 32.290 1 Template:Infobox_drug/chemical_formula"," 4.76% 26.056 1 Template:Growth_factor_receptor_modulators"," 3.29% 18.008 1 Template:Cytokine_receptor_modulators"],"scribunto":"limitreport-timeusage":"value":"0.206","limit":"10.000","limitreport-memusage":"value":4997756,"limit":52428800,"cachereport":"origin":"mw2194","timestamp":"20181010125128","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":105,"wgHostname":"mw2238"););
-

Popular posts from this blog

泉州府

Image
Clash Royale CLAN TAG #URR8PPP   「 泉州 」重定向至此。關於与此名称相似的其他条目，詳見「 泉州 (消歧义) 」。 泉州府 閩南語名稱 ? 全漢 泉州府 全羅 Choân-chiu-hú 泉州府 是明清时期福建省下辖的一个府，範圍大概是今日的泉州、廈門與金門。 目录 1 历史沿革 2 历任知府 3 志书 4 地标 5 参考文献 历史沿革 明朝洪武初...
Read more

大跃进

Image
Clash Royale CLAN TAG #URR8PPP 大跃进时期的宣传海报：“以钢为纲，全面跃进” 大躍進 是於1958年至1960年，在中國共產黨領導下，在中華人民共和國發生的試圖利用本土充裕勞動力和蓬勃的群眾熱情在工業和農業上不切实际地增产（即「躍進」）的社會主義建設運動。总路线、大跃进和人民公社化三项政策的...
Read more

马相伯

Image
Clash Royale CLAN TAG #URR8PPP body.skin-minerva .mw-parser-output table.infobox captiontext-align:center 马相伯 教育家 國家 中國 姓 马 名 良 字 相伯 其他名號 天主教圣名： 若瑟 出生 道光二十年 ( 1840-04-17 ) 1840年4月17日 清朝江苏省镇江府丹阳县北乡马家村 逝世 民國二十八年 1939年11月4日 ( 1939-11-04 ) （99歲） 法屬印度支那谅山 墳墓 上海宋庆龄陵园 親屬 父親 马松岩 母親 沈氏 嫡兄弟 马建...
Read more